Abzena, a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Trieza Therapeutics.
Trieza is a start-up biotechnology company specialising in the discovery and development of immunomodulatory oncolytic viruses based in Cambridge (MA, USA).
Abzena has granted Trieza an exclusive worldwide, royalty bearing, sublicensable licence to an undisclosed antibody sequence, which was created using the Group’s Composite Human Antibody technology, for exploitation in conjunction with Trieza’s viral vector technology to develop novel therapies in oncology.
Abzena could receive up to $35 million in development and commercial milestone payments, as well as royalties on the sale of licensed products containing the Abzena sequence.
Dr John Burt, Abzena’s CEO, commented: “This new licence deal with Trieza provides the opportunity for Abzena to benefit from the commercialisation of one of the assets originally developed by the group to exemplify its proprietary antibody humanisation and deimmunisation technology. Our Abzena inside portfolio already has eleven products in the clinic that have benefitted from this technology.”
Dr Dan Hicklin, Trieza Therapeutics’ CEO, said: “We are pleased to enter this relationship with Abzena. Access to Abzena’s technology will accelerate the development of Trieza’s portfolio of immunotherapeutic oncolytic virus product candidates.”